Patents by Inventor Lars Heslet

Lars Heslet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140205658
    Abstract: Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.
    Type: Application
    Filed: August 29, 2012
    Publication date: July 24, 2014
    Applicant: TRIFOILIUM APS
    Inventor: Lars Heslet
  • Publication number: 20140023612
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 23, 2014
    Applicant: TRIFOILIUM ApS
    Inventor: Lars Heslet
  • Publication number: 20130274171
    Abstract: The present invention provides methods for enhancing or inducing airway epithelial repair and/or regeneration and/or for the normalization of airway epithelial remodeling, using local deposition of one or more pro-regenerative factors, preferably a peptide or protein from the trefoil family factor (TFF) family. The pro-regenerative factor is administered to a patient as a treatment of Chronic obstructive pulmonary disease (COPD), chronic bronchitis, Cystic fibrosis, Asthma, Bronchiectasis, Panbronchiolitis, pneumonia, ventilator associated pneumonia (VAP), hospital acquired pneumonia (HAP), community acquired pneumonia (CAP), severe community acquired pneumonia (sCAP) and pneumocystis carinii or to patients suffering from lung damage reducing the function of the mucociliary transport system based on fully functioning cilia secondary to, e.g. inhalation of toxic fumes. The present invention also provide therapy and or prophylactic or preemptive, i.e.
    Type: Application
    Filed: June 3, 2011
    Publication date: October 17, 2013
    Applicant: TRIFOILIUM APS
    Inventors: Kaare Fiala, Lars Heslet
  • Publication number: 20130216608
    Abstract: The present invention provides methods for the local pulmonary treatment of lung metastases and/or primary lung cancer, such as squamous lung cancer and/or small cell lung cancer, using local deposition of one or more agents capable of inhibiting angiogenesis and/or an agent that acts as an active anti-cancer agent and/or an active anti-metastatic agent. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered to a patient with cancer as a treatment of said metastasis and/or cancer or to extend the lifespan for said cancer patient with reduced systemic side-effects compared to other treatment forms. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered intratracheal, intrabronchial, intraalveolar or broncioalveolar.
    Type: Application
    Filed: September 9, 2011
    Publication date: August 22, 2013
    Applicant: Trifoilium ApS
    Inventors: Lars Heslet, Kaare Fiala
  • Patent number: 8431535
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: April 30, 2013
    Assignee: Hoiberg A/S
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Patent number: 7807639
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject. Methods of the present invention are useful in treating diffuse alveolar hemorrhage secondary to blast lung injury, HIV infection and AIDS.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: October 5, 2010
    Assignee: Pharmaorigin ASP
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Publication number: 20070258971
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.
    Type: Application
    Filed: September 9, 2005
    Publication date: November 8, 2007
    Applicant: PHARMAORGIN APS
    Inventors: Lars Heslet, Lars Uttenthal
  • Publication number: 20070060517
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject. Methods of the present invention are useful in treating diffuse alveolar hemorrhage secondary to blast lung injury, HIV infection and AIDS.
    Type: Application
    Filed: May 26, 2006
    Publication date: March 15, 2007
    Inventors: Lars Heslet, Lars Uttenthal